ReviewHuman genomics2021
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy.
Review in Human genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic accuracy of clinical signs and symptoms of COVID-19: A systematic review and meta-analysis to investigate the different estimates in a different stage of the pandemic outbreak.Journal of global health · 2023Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review.International journal of immunopathology and pharmacologyPooled it
- Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.The Journal of clinical investigation · 2021Trial
- Genetic Screening forFrontiers in immunology · 2021Trial
- India should invest in the expansion of genomic epidemiology for vector-borne diseases filariasis, malaria and visceral leishmaniasis that are targeted for elimination.IJID regions · 2024Review
- ENaC gene variants and their involvement in Covid‑19 severity.Biomedical reports · 2024Article
- Unraveling the protective genetic architecture of COVID-19 in the Brazilian Amazon.Scientific reports · 2024Article
- No Association between SARS-CoV-2 Infection and the Polymorphism of the Toll-like Receptor 7 (Diagnostics (Basel, Switzerland) · 2023Article
- Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.Microorganisms · 2023Review
- COVID-19 annual update: a narrative review.Human genomics · 2023Review
- SFTPB (rs11130866) and NR3C1 (rs41423247) gene variants as potential clinical biomarkers for personalized treatment strategy selection in patients with severe COVID-19 pneumonia.Respiratory investigation · 2023Article
- Probability of hospitalisation and death among COVID-19 patients with comorbidity during outbreaks occurring in Mexico City.Journal of global health · 2022Article
- Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination.Microbiology spectrum · 2022Observational
- Characterization of ACE2 naturally occurring missense variants: impact on subcellular localization and trafficking.Human genomics · 2022Article
- Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines.Reviews in medical virology · 2022Review
- Evaluation of the effectiveness of surveillance policies to control the COVID-19 pandemic in São Paulo, Brazil.Global health research and policy · 2022Article
- Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.International journal of molecular sciences · 2022Review
- COVID-19 2022 update: transition of the pandemic to the endemic phase.Human genomics · 2022Review
- COVID-19 and Molecular Genetics.Genes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
COVID-19 has engulfed the world and it will accompany us all for some time to come. Here, we review the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organization). We review several aspects of the on-going pandemic, focusing first on two major topics: viral variants and the human genetic susceptibility to disease severity. We then consider recent and exciting new developments in therapeutics, such as monoclonal antibodies, and in prevention strategies, such as vaccines. We also briefly discuss how advances in basic science and in biotechnology, under the threat of a worldwide emergency, have accelerated to an unprecedented degree of the transition from the laboratory to clinical applications. While every day we acquire more and more tools to deal with the on-going pandemic, we are aware that the path will be arduous and it will require all of us being community-minded. In this respect, we lament past delays in timely full investigations, and we call for bypassing local politics in the interest of humankind on all continents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.